Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / Common stock, par value $0.001 per share
Symbol
APRE on Nasdaq
Shares outstanding
9,144,889
Price per share
$0.59
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,695,512
Total reported value
$1,446,275
% of total 13F portfolios
0%
Share change
+66,461
Value change
-$113,007
Number of holders
22
Price from insider filings
$0.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
LYTTON LAURENCE W 9.9% $913,662 681,837 LYTTON LAURENCE W 13 Nov 2025
Nantahala Capital Management, LLC 4.5% -40% $386,829 411,520 0% Nantahala Capital Management, LLC 31 Dec 2025
Stonepine Capital Management, LLC 4.3% -16% $418,978 -$82,213 239,416 -16% Stonepine Capital Management, LLC 31 Mar 2025
Sio Capital Management, LLC 1.9% -62% $165,529 -$246,540 112,223 -60% Sio Capital Management, LLC 30 Sep 2025

As of 31 Dec 2025, 22 institutional investors reported holding 1,695,512 shares of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE). This represents 19% of the company’s total 9,144,889 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) together control 19% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
AIGH Capital Management LLC 4.1% 370,541 -31% 0.09% $316,071
Murchinson Ltd. 3.7% 340,139 0.18% $290,139
SPHERA FUNDS MANAGEMENT LTD. 3% 270,000 0% 0.05% $230,310
Nantahala Capital Management, LLC 2.2% 205,760 0% 0.01% $175,513
DRW Securities, LLC 1.3% 120,651 0.01% $102,915
MORGAN STANLEY 0.84% 77,030 +17% 0% $65,706
VANGUARD GROUP INC 0.64% 58,086 -63% 0% $49,548
CITADEL ADVISORS LLC 0.56% 51,041 0% $43,538
JANE STREET GROUP, LLC 0.51% 46,621 0% $39,767
GEODE CAPITAL MANAGEMENT, LLC 0.45% 40,950 -8.2% 0% $34,935
BNP PARIBAS FINANCIAL MARKETS 0.3% 27,332 0% 0% $23,314
LPL Financial LLC 0.28% 26,052 +62% 0% $22,222
XTX Topco Ltd 0.27% 24,304 0% $20,731
HighTower Advisors, LLC 0.15% 13,864 0% 0% $11,826
BlackRock, Inc. 0.09% 8,504 0% 0% $7,255
Tower Research Capital LLC (TRC) 0.09% 7,827 +1278% 0% $6,676
BANK OF AMERICA CORP /DE/ 0.04% 3,299 -32% 0% $2,814
UBS Group AG 0.03% 2,461 +81933% 0% $2,100
GROUP ONE TRADING LLC 0.01% 577 0% 0% $492
OSAIC HOLDINGS, INC. 0% 300 -25% 0% $255
WealthCollab, LLC 0% 158 0% 0% $135
SBI Securities Co., Ltd. 0% 15 -64% 0% $13
Sio Capital Management, LLC 0% 0 -100% $0
MB, LEVIS & ASSOCIATES, LLC 0% 0 -100% $0
CITIGROUP INC 0% 0 -100% $0

Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,695,512 $1,446,275 -$113,007 $0.85 22
2025 Q3 1,618,851 $2,387,744 -$296,033 $1.48 23
2025 Q2 1,815,508 $3,072,270 -$77,601 $1.69 23
2025 Q1 1,847,462 $3,768,839 -$165,845 $2.04 25
2024 Q4 2,077,381 $6,829,282 +$211,103 $3.29 26
2024 Q3 2,000,189 $5,500,414 -$431,314 $2.75 21
2024 Q2 2,083,045 $8,477,419 +$1,866,030 $4.07 27
2024 Q1 1,624,394 $10,764,195 +$4,966,764 $6.69 22
2023 Q4 926,780 $4,355,977 +$26,645 $4.70 19
2023 Q3 876,935 $3,660,270 -$19,509 $4.17 19
2023 Q2 881,553 $2,776,892 +$105,033 $3.15 17
2023 Q1 848,237 $3,769,266 +$3,769,266 $4.44 15